NCK associated protein 1 likeGenealiases: HEM1 · IMD72
Q-omics provides the consensus-scored NCKAP1L profile across patient tissues and cancer cell-line models. NCKAP1L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NCKAP1L is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NCKAP1L protein abundance shows 25,500 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where NCKAP1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCKAP1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCKAP1L survival associations across molecular data types. NCKAP1L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCKAP1L RNA expression–survival associations across cancer types. High NCKAP1L expression shows unfavorable associations in LGG and UVM, but favorable associations in HNSC, SKCM, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NCKAP1L RNA expression.
This table summarizes NCKAP1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NCKAP1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCKAP1L shows lower tumor expression in LUAD, COAD, LUSC and BLCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher NCKAP1L RNA expression in tumor versus normal tissue (log2 FC = +2.457, t-test p < 0.001).
This table shows molecular features associated with NCKAP1L in patient tissues and cancer cell lines. In patient samples, NCKAP1L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCKAP1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
